Boehringer takes a different approach in cystic fibrosis gene therapy
Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.
Atea and Roche get a Covid-19 antiviral warning
The failure of the phase 2 Moonsong outpatient trial prompts a phase 3 rethink and a one-year delay.
ANA 2021 – Ionis rocked by tofersen flop
After the Valor defeat, the group and its partner Biogen will hope that going earlier could improve the amyotrophic lateral sclerosis project’s chances.
Memed seeks partners for bacterial vs viral testing and more
The group’s ambitions are startling, but it will need cash and collaborators to realise them.
Another big year beckons for biotech venture financing
Private drug developers have already raised more money this year than in 2020.
Idorsia’s Fabry flop puts focus on gene therapies
But questions about gene therapy safety could benefit the enzyme-replacement therapy incumbents.
Supernus and Pacira swoop while their targets are down
Two opportunistic buys today, of Adamas and Flexion, included a contingent value rights component.
